Aposta · Sep 10, 2026
Tirzepatide and the quality of weight loss: preservation of lean mass, body composition, and risk of frailty
By Nascimento EDSRD, Girardi J, Amaral VS et al.
This study aimed to analyze the available evidence on the effects of tirzepatide on body composition, with an emphasis on fat mass, lean mass, muscle quality, and risk of frailty. An integrative literature review was conducted, with searches in MEDLINE/PubMed, Scopus, and Web of Science. A total of 623 records were identified, of which 493 remained after duplicates were removed. After screening titles and abstracts, 67 articles were assessed in full, and 9 studies were included in the qualitative synthesis. The results demonstrated that most of the weight loss associated with tirzepatide corresponds to a reduction in fat mass, including visceral and ectopic fat, although a reduction in lean mass may also occur. Magnetic resonance imaging studies suggested improvement in muscle fat infiltration, while recent clinical data indicated maintenance of strength in some groups. However, evidence on sarcopenia and frailty remains limited. It is concluded that tirzepatide has a favorable profile regarding the quality of weight loss, with a predominance of body fat reduction, although additional studies are needed to clarify its long-term effects on muscle mass, physical function, and frailty.